This site has been optimized to work with modern browsers and does not fully support your version of Internet Explorer.

Early health economic evaluation of an AI-enabled contactless home-monitoring tool for children with asthma

Summary

Asthma is the most common long-term condition in childhood in the UK and one of the leading causes of emergency hospital admission in children. Asthma care is estimated to cost the UK more than £1 billion a year. In children, much of the avoidable cost arises from emergency department attendances and unplanned admissions, many of which could be prevented through earlier recognition of worsening asthma.

Albus Health, an Oxford-based medical technology company, has developed Albus Home, a contactless, AI-enabled bedside device that passively captures a child’s night-time symptoms, including coughing, breathing, and indoor environmental conditions overnight to detect early signs of deteriorations. Health Innovation Oxford and Thames Valley (HIOTV) was a co-applicant with Albus Health in the AI in Health and Care Award to undertake an early hypothetical health economic evaluation of Albus Home. The evaluation explored its potential value to the NHS for children with moderate-to-severe asthma under specialist care. The work was designed to inform product development, identify the evidence required for future adoption decisions and provide an early indication of the circumstances under which the technology could deliver value to the NHS.

Problem being addressed

Most severe asthma attacks in children develop over hours to several days, creating a window in which early action could prevent an emergency. Yet this window is often missed. Existing home monitoring relies on symptom diaries and peak-flow readings that depend on daily effort from families and are frequently incomplete, while symptoms that worsen overnight can go unnoticed between routine clinic reviews. As a result, care remains largely reactive, with many children only receiving help once they reach the emergency department. The impact is greatest among children with moderate-to-severe asthma, who experience the most frequent attacks and account for a disproportionate share of emergency attendances, admissions and costs.

Albus Home aims to close this gap by passively capturing objective overnight data, without any input from the child, so that deteriorations can be identified and acted on earlier. However, at this stage of development, decision-makers and innovators require an understanding not only of whether a technology works, but also of how it could fit into the existing service, how it might create value within NHS care pathways, what it could save, and what evidence will be needed to support future adoption. Early health economic analysis can help answer these questions before significant investment is made in clinical studies.

Our support

HIOTV carried out an early health economic evaluation of Albus Home, beginning with mapping the current paediatric asthma care pathway and reviewing the evidence on digital home monitoring. This ensured that Albus Home was compared with today’s standard of care, and helped define the population in which Albus Home is most likely to deliver value: children with moderate-to-severe asthma under specialist care, who have the highest risk of attacks.

HIOTV then developed a proportionate, early-stage decision-tree cost–consequence model, using national NHS data and reference costs, to compare Albus Home with current home monitoring over one year from an NHS perspective. Sensitivity analyses tested how the findings changed under different assumptions.

Impacts

The work provided Albus Health with an early understanding of how Albus Home could create value within the NHS and which components of the care pathway were most likely to drive that value. The evaluation helped translate the technology’s clinical proposition into outcomes that are relevant to NHS decision-makers, including emergency care utilisation and hospital admissions.

Importantly, the analysis also identified the areas where further evidence would be required, enabling the company to align its future evidence-generation strategy with the needs of NHS commissioners, providers and other stakeholders.

Health and care system success

Evidence suggests that changes in night-time breathing and cough could provide an early warning of deteriorating asthma, potentially before symptoms are noticed by children and caregivers. Comparable digital monitoring programmes have also been associated with fewer unscheduled emergency attendances and hospital admissions in children with asthma. Taken together with the economic analysis, this suggests that Albus Home could help shift paediatric asthma care from reactive emergency treatment towards earlier, planned intervention at home, if these effects are confirmed in real-world studies.

This would ease pressure on urgent and emergency care and reduce paediatric bed days. For children and families, fewer attacks would be expected to improve quality of life, reduce missed school days and parents’ time off work, and lessen anxiety about unpredictable night-time symptoms and debilitating asthma attacks.

Economic success

The work enabled Albus Health to explore the relationship between clinical impact, NHS resource use and future pricing considerations within a structured evidence-based framework.

The analysis indicated that Albus Home has the potential to reduce annual asthma-related NHS costs compared with current care, driven by fewer emergency attendances and hospital admissions. The model projected cost savings across the sensitivity analyses tested. The analysis did not capture longer-term outcomes, quality-adjusted life years or wider societal impacts. These areas should be explored in future evaluations as further evidence becomes available.

Lessons learned

The project highlighted the value of undertaking health economic analysis early in the innovation lifecycle, rather than waiting until clinical evidence generation is complete. Mapping the care pathway and reviewing the evidence base helped define the population most likely to benefit and identify a realistic comparator, so that future evaluation is focused where need and impact are greatest. Starting with a simple, proportionate model made the key assumptions transparent. The analysis also showed that the potential value of Albus Home is sensitive to assumptions about clinical impact and NHS resource use. Identifying these value drivers early shows where future evidence generation should focus, so that evidence and economic strategy can develop together.

Next steps

This work provides a strong foundation for the next stage of evidence generation and demonstrates how early health economic evaluation can be used to shape both product development and evidence strategy.

HIOTV recommends, as a priority, a real-world or trial-based evaluation in children with moderate-to-severe asthma, with an embedded economic analysis to confirm the expected reductions in emergency care and to capture real-world costs.

Future modelling should draw on clinical inputs from a pilot or real-world data, extend beyond one year and include quality-adjusted life years and wider societal costs, to reflect the full value of proactive monitoring. Integration into NHS workflows, value-based pricing and commissioning routes should also be assessed to support equitable access and wider adoption.

What they said

Working with the Health Innovation Oxford and Thames Valley team has been a really positive experience. We have valued the close collaborative working relationship right from project conception and proposal stage, through to project delivery and completion of a multi-year project. Their expertise has helped us better understand the key stakeholders and pathways to adoption, evaluate how Albus Home could deliver value for healthcare systems and payers, and what evidence will be most important to demonstrate that value. Undertaking this evaluation at an early stage has been particularly useful in shaping our thinking and informing our next steps.” – William Do, Co-founder and Medical Director of Albus Health

Contact

Dr Rayan Altayeb, Health Economist and Methodologist: Rayan.Altayeb@healthinnovationoxford.org

Case study categories: Supporting innovators Digital Care close to home Respiratory